MK-3475A clinical trials

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

This study is testing a new drug combination for a specific type of lung cancer that has been removed by surgery. It compares two treatments: a new drug (Calderasib) with an existing one (MK-3475A), against the existing drug plus a dummy treatment, to see if it helps stop the cancer from coming back.